Prosensa has provided the following update regarding the impact of the drisapersen phase 3 data on its programs:
While we are disappointed and surprised with the unexpected outcome of the drisapersen phase 3 study, we remain very committed to drisapersen, the Duchenne program at large, and the Duchenne community. We will continue to work closely with GSK to better understand the data, also within the context of the other placebo-controlled trials and the open label studies. GSK has indicated that additional time is needed for a full evaluation of the benefit-to-risk profile of drisapersen treatment across all studies. GSK has announced that they anticipate that this evaluation will be completed by year end. During the upcoming period in which the data of the various drisapersen studies will be analyzed in more detail, the Prosensa programs will continue.
We anticipate that the results of the analysis will provide more insight into the effects of drisapersen and the impact on Prosensa’s programs.
We are very grateful for the families who support the Prosensa programs. We will continue to communicate new information as it is determined.
If you have questions for GSK, please send them to Sharon@ParentProjectMD.org by 5pm eastern today and we will make sure the company receives them. GSK may be able to supply some answers before the October 15th webinar.